(Q34781440)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18500240%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

title

Translation of targeted oncolytic virotherapeutics from the lab into the clinic, and back again: a high-value iterative loop (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18500240%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1 reference

Tae-Ho Hwang

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18500240%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

David H Kirn

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18500240%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

publication date

1 June 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18500240%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18500240%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18500240%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18500240%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

page(s)

1006-1008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18500240%20AND%20SRC:MED&resulttype=core&format=json

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

7 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.70

7 January 2021

History of oncolytic viruses: genesis to genetic engineering

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.70

7 January 2021

Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.70

7 January 2021

Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.70

7 January 2021

An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.70

7 January 2021

Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.70

7 January 2021

E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.70

7 January 2021

CD46 is a cellular receptor for group B adenoviruses

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.70

7 January 2021

Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.70

7 January 2021

Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.70

7 January 2021

A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.70

7 January 2021

Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.70

7 January 2021

An ex vivo human model system to evaluate specificity of replicating and non-replicating gene therapy agents

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.70

7 January 2021